Tolerability of Enecadin (INN) in Acute Ischemic Stroke Trial - TEST
NCT ID: NCT00331721
Last Updated: 2008-05-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
24 participants
INTERVENTIONAL
2006-05-31
2009-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intravenous Ancrod for the Treatment of Acute Ischemic Stroke Within 6 Hours After Onset of Symptoms
NCT00343174
Safety and Tolerability of BIII 890 in Patients With Acute Ischemic Stroke
NCT02251197
Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
NCT00893867
Trial of EXenatide in Acute Ischaemic Stroke
NCT03287076
Study Evaluating The Safety And Efficacy Of PF-03049423 In Subjects With Ischemic Stroke
NCT01208233
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Enecadin
Enecadin
Dose escalating
2
Placebo
Placebo
Placebo comparator
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Enecadin
Dose escalating
Placebo
Placebo comparator
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* For female patients: post-menopausal or surgically sterile (post-menopausal: age ≥55 years and last menses ≥3 years ago).
Exclusion Criteria
* Patients unable to understand trial related information.
* History or evidence of severe heart diseases further specified in the protocol.
* History or evidence of additional diseases or results of baseline visit as specified in the protocol.
* Use of concomitant and prior medications as defined in the protocol.
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
PAION Deutschland GmbH
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
PAION Deutschland GmbH
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peter A Ringleb, Dr.
Role: PRINCIPAL_INVESTIGATOR
Heidelberg University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Investigational Site 1
Linz, , Austria
Investigational Site 2
Linz, , Austria
Investigational Site
Antwerp, , Belgium
Investigational Site
Bruges, , Belgium
Investigational Site
Leuven, , Belgium
Investigational Site
Aachen, , Germany
Investigational Site
Bad Neustadt an der Saale, , Germany
Investigational Site
Bergisch Gladbach, , Germany
Investigational Site
Berlin, , Germany
Investigational Site
Bochum, , Germany
Investigational Site
Dortmund, , Germany
Investigational Site
Dresden, , Germany
Investigational Site
Erlangen, , Germany
Investigational Site
Frankfurt, , Germany
Investigational Site
Freiburg im Breisgau, , Germany
Investigational Site
Hamburg, , Germany
Investigational Site
Hanover, , Germany
University of Heidelberg
Heidelberg, , Germany
Investigational Site
Ingolstadt, , Germany
Investigational Site
Leipzig, , Germany
Investigational Site
Magdeburg, , Germany
Investigational Site
Minden, , Germany
Investigational Site
Munich, , Germany
Investigational Site
Nuremberg, , Germany
Investigational Site
Remscheid, , Germany
Investigational Site
Wiesbaden, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PN06-CLD-01001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.